These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 2139173)

  • 21. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
    Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
    AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study.
    Wang Y; Livingston E; Patil S; McKinney RE; Bardeguez AD; Gandia J; O'Sullivan MJ; Clax P; Huang S; Unadkat JD
    J Infect Dis; 1999 Nov; 180(5):1536-41. PubMed ID: 10515813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.
    McKinney RE; Maha MA; Connor EM; Feinberg J; Scott GB; Wulfsohn M; McIntosh K; Borkowsky W; Modlin JF; Weintrub P
    N Engl J Med; 1991 Apr; 324(15):1018-25. PubMed ID: 1672443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ddI--a good start, but still phase I.
    Fauci AS
    N Engl J Med; 1990 May; 322(19):1386-8. PubMed ID: 2109198
    [No Abstract]   [Full Text] [Related]  

  • 25. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
    Fischl MA; Parker CB; Pettinelli C; Wulfsohn M; Hirsch MS; Collier AC; Antoniskis D; Ho M; Richman DD; Fuchs E
    N Engl J Med; 1990 Oct; 323(15):1009-14. PubMed ID: 1977079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
    Richman DD; Fischl MA; Grieco MH; Gottlieb MS; Volberding PA; Laskin OL; Leedom JM; Groopman JE; Mildvan D; Hirsch MS
    N Engl J Med; 1987 Jul; 317(4):192-7. PubMed ID: 3299090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI).
    Reddy MM; McKinley GF; Grieco MH
    J Clin Lab Anal; 1991; 5(6):396-8. PubMed ID: 1774603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A trial with ribavirin in patients with AIDS or AIDS-related complex.
    Crocchiolo P; Pristera R; Lazzarin A; Chemotti M; Froldi M; Palazzini E; Verani P; Orecchia A; Moroni M
    Boll Ist Sieroter Milan; 1989; 68(2):185-90. PubMed ID: 2491303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
    Moyle GJ; Nelson MR; Hawkins D; Gazzard BG
    Q J Med; 1993 Mar; 86(3):155-63. PubMed ID: 8387218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
    Butler KM; Husson RN; Balis FM; Brouwers P; Eddy J; el-Amin D; Gress J; Hawkins M; Jarosinski P; Moss H
    N Engl J Med; 1991 Jan; 324(3):137-44. PubMed ID: 1670591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.
    Merigan TC; Skowron G; Bozzette SA; Richman D; Uttamchandani R; Fischl M; Schooley R; Hirsch M; Soo W; Pettinelli C
    Ann Intern Med; 1989 Feb; 110(3):189-94. PubMed ID: 2536257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Didanosine in the treatment of AIDS and AIDS-related complex: a critical appraisal of the dose and frequency of administration.
    Liebman HA; Cooley TP
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S52-8. PubMed ID: 8093847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.
    Drusano GL; Yuen GJ; Morse G; Cooley TP; Seidlin M; Lambert JS; Liebman HA; Valentine FT; Dolin R
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1280-3. PubMed ID: 1416828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation.
    Crumpacker C; Heagy W; Bubley G; Monroe JE; Finberg R; Hussey S; Schnipper L; Lucey D; Lee TH; McLane MF
    Ann Intern Med; 1987 Nov; 107(5):664-74. PubMed ID: 3662279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.
    Knupp CA; Shyu WC; Dolin R; Valentine FT; McLaren C; Martin RR; Pittman KA; Barbhaiya RH
    Clin Pharmacol Ther; 1991 May; 49(5):523-35. PubMed ID: 1903100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New developments in the clinical use of didanosine.
    Kahn J
    J Acquir Immune Defic Syndr (1988); 1993; 6 Suppl 1():S47-50. PubMed ID: 8426301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex.
    Beltangady M; Knupp CA; Gustafson N; Barbhaiya RH; Dolin R; Seidlin M; Cooley TP; Rozencweig M
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S26-31. PubMed ID: 8093845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Didanosine: long-term follow-up of patients in a phase 1 study.
    Lambert JS; Seidlin M; Valentine FT; Reichman RC; Dolin R
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S40-5. PubMed ID: 8093846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.